Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article is for informational purposes only. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before changing your diet, exercise, or supplement regimen, particularly if you have a chronic health condition, are pregnant, nursing, or taking any medications.

TL;DR

• Fisetin is a flavonoid polyphenol found at high concentrations in strawberries (~160 μg/g fresh weight), apples, persimmons, kiwi, onions, and cucumbers — many of them core products of Shizuoka and Tochigi prefecture agriculture
• A 2017 Mayo Clinic screening study by Kirkland and colleagues (EBioMedicine) compared ten natural polyphenols on senolytic activity in cell culture and identified fisetin as the most potent candidate: it preferentially induced apoptosis in senescent cells at concentrations that left non-senescent cells substantially intact
• A 2018 study by Yousefzadeh et al. (EBioMedicine) found that fisetin was associated with selective clearance of senescent cells in preclinical research, reducing senescent cell burden in mouse tissues by approximately 52%, and was linked to extended healthspan in aged mice — including when dosing began late in life
• Proposed mechanisms include senolytic activity, SIRT1 and SIRT3 activation, mTOR inhibition, NF-κB inflammatory signaling suppression, Nrf2 antioxidant pathway activation, and blood-brain barrier penetration with potential effects on BDNF and NGF in rodent models
• Calibration: Yousefzadeh 2018 is a mouse model. Phase 2 human trials at Mayo Clinic (NCT02848131, NCT02652052) are ongoing as of mid-2026, with early-phase human trials currently underway. No randomized controlled trial has established that fisetin supplementation clears senescent cells or extends healthspan in living human subjects. Dosing and timing protocols in humans are not yet established.

The question the 2017 screening actually posed

Most readers who encounter fisetin arrive from one of two directions: either they read about senolytics broadly and want to understand why fisetin specifically attracted Mayo Clinic research attention, or they are following Japanese agricultural and dietary content and found the strawberry connection to aging biology research. Both paths lead to the same practical question — does the preclinical evidence justify the supplement interest?

That question deserves a precise answer rather than a binary yes or no, because what the 2017 and 2018 papers actually established is genuinely interesting, and what they left unresolved is equally real.

Senolytics research took shape around a 2011 Nature paper demonstrating that genetic elimination of p16^INK4a-positive senescent cells in aging mice was associated with delayed functional decline across multiple tissue systems. The mechanistic framework — how senescent cells accumulate, what the senescence-associated secretory phenotype (SASP) does to surrounding tissue, and where pharmacological senolytics fit in — is covered in the cellular senescence and senolytics research article. What matters for the fisetin discussion is where fisetin enters that framework: it was identified through systematic comparative screening, not through folk medicine tradition or supplement marketing.

The 2017 Mayo Clinic screening: how fisetin outranked ten other polyphenols

The Kirkland laboratory at the Mayo Clinic Robert and Arlene Kogod Center on Aging published a screening analysis asking a specific question: which natural polyphenols showed preferential cytotoxicity toward senescent cells rather than non-senescent cells in culture?

The screen tested ten compounds across senescent human adipose-derived stromal cells, senescent mouse embryonic fibroblasts, and non-senescent counterparts of each cell type. The candidate list included quercetin (already established in senolytic protocols when paired with dasatinib), luteolin, apigenin, rutin, curcumin, and others. The result: fisetin produced the most selective kill ratio across the cell types tested — preferential apoptosis in senescent cells at concentrations that left non-senescent cells substantially intact.

This matters for framing. Fisetin did not arrive in aging research through the traditional herbal medicine route or through search engine optimization. It came from head-to-head comparative laboratory work, evaluated alongside the most studied natural compounds in the senolytic space. That origin does not guarantee human clinical translation — many compounds with compelling cell culture profiles have not replicated in whole organisms or in human trials — but it gives fisetin a methodological grounding that most “natural senolytic” claims lack.

Yousefzadeh et al. 2018: what the mouse data shows, and what it does not

The more widely cited 2018 paper by Yousefzadeh, Zhu, McGowan, and colleagues in EBioMedicine moved from cell culture to whole-organism models. The study administered fisetin to aging mice using multiple protocols, including treatment beginning late in life — in timing equivalent to starting supplementation in old age rather than midlife.

The primary findings: fisetin administration was associated with a roughly 52% reduction in senescent cell burden across multiple tissues as measured by p16 and p21 expression markers. It was also linked to extended median and maximum lifespan in normally aged cohorts and to improved physical function markers in aged mice relative to controls. The late-life dosing finding attracted particular attention because it suggested the intervention did not need to begin in youth to produce measurable effects in rodents.

Two aspects of this result require direct calibration. First, it is a mouse model. The track record of mouse longevity findings translating to human outcomes is imperfect — the field has numerous examples of lifespan extension in rodents that did not replicate in primate or human biology. Second, the doses used in the mouse study, when scaled using standard interspecies pharmacokinetic conversion factors, imply human-equivalent doses in the high hundreds of milligrams per day range — considerably above what dietary strawberry consumption can realistically deliver, and at the upper end of what commercial supplements currently provide.

What the 2018 data does establish: fisetin administration at specific doses in aged mouse models produces selective reduction in senescent cell markers as measured by established molecular assays, alongside functional outcomes in those models. That is reproducible and specific. It is not yet a clinical recommendation.

Japan’s strawberry farms and the fisetin concentration context

The fisetin-Japan connection reflects something real in agricultural chemistry. Strawberries consistently show the highest fisetin concentrations of commonly measured foods in food chemistry analyses, typically in the range of around 160 μg per gram fresh weight — a figure reproduced across multiple independent food composition analyses. Japan’s premium strawberry production is concentrated in Shizuoka and Tochigi prefectures, which together represent a large share of domestic output. Varieties including Tochiotome, Benihoppe, and Sagahonoka are bred for sweetness, size, and shelf life rather than specifically for fisetin content; variety-level fisetin measurements for Japanese cultivars are not systematically published.

Beyond strawberries, fisetin is present at lower but measurable concentrations in other foods common in Japanese diets: apples, persimmons (kaki), kiwi, onions (tamanegi), and cucumbers. None approach strawberry concentrations, but their combined contribution means a Japanese dietary pattern with high fresh fruit and vegetable variety delivers more dietary fisetin than most Western dietary patterns by published food composition estimates.

The dietary intake point, however, connects imperfectly to the mouse study doses. You cannot realistically consume through strawberry intake the quantities that produced senolytic effects in the Yousefzadeh model. This does not make the dietary angle irrelevant — it establishes that fisetin is a compound with a real food history rather than a synthetic construct — but the food source and the supplement question are genuinely separate.

What fisetin appears to do at the cellular level

Several molecular mechanisms have been proposed for fisetin’s senolytic activity, each supported by preclinical evidence at varying depths.

Selective pro-apoptotic activity in senescent cells: senescent cells survive by upregulating pro-survival pathways — including BCL-2 family anti-apoptotic proteins and PI3K/AKT signaling — that protect them from cell death signals that would otherwise eliminate damaged cells. Fisetin appears to suppress these pro-survival signals preferentially in senescent cells, shifting the balance toward apoptosis. Non-senescent cells, which are less reliant on these specific survival upregulations, are comparatively spared at equivalent doses.

SIRT1 and SIRT3 activation: fisetin has been shown to activate sirtuin deacetylases in cell culture and rodent models. The sirtuin pathway — covered in the sirtuins, NAD+, and caloric restriction article — is associated with SASP suppression through SIRT1-mediated NF-κB deacetylation. Reduced SASP secretion would mean that surviving senescent cells release fewer pro-inflammatory cytokines into surrounding tissue, potentially reducing the local inflammatory burden even in cells that are not eliminated.

mTOR inhibition and NF-κB blockade: fisetin appears to inhibit mechanistic target of rapamycin (mTOR) signaling and to block NF-κB inflammatory pathway activation in cell culture models. Both are associated with SASP component reduction and altered senescent cell behavior in multiple model systems. The dose-dependence and specificity of these effects in human physiological conditions remain to be established.

Nrf2 antioxidant pathway: fisetin activates Nrf2 transcription factor activity in cell culture, driving expression of endogenous antioxidant enzymes. This mechanism is distinct from the senolytic activity and may contribute independently to oxidative stress protection observed in preclinical models.

Blood-brain barrier penetration: fisetin’s lipophilicity allows it to cross the blood-brain barrier, and it has been reported to be linked to increased BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) expression in rodent brain tissue. Whether this translates to neurotrophic effects in humans at supplementation doses is not established from published human data.

These mechanisms overlap with other polyphenols in some dimensions, but the documented senolytic selectivity from the 2017 comparative screen — evaluated against compounds that share some of these same proposed mechanisms — makes fisetin’s preclinical profile more specifically characterized than most natural supplements discussed in aging biology.

Where Mayo Clinic’s human trials actually stand

Two Phase 2 clinical trials examining fisetin are registered with ClinicalTrials.gov under identifiers NCT02848131 and NCT02652052, associated with Mayo Clinic research. These are early-phase studies examining fisetin in specific human populations, with endpoints focused on senescent cell biomarker changes in tissue and plasma rather than clinical disease outcomes or lifespan endpoints.

As of mid-2026, peer-reviewed results from these Phase 2 trials specifically examining fisetin have not been published in the accessible literature. Phase 2 trials in the senolytic space establish whether compounds produce detectable reduction in human senescent cell burden markers — target engagement — rather than powered efficacy or hard clinical outcome claims. The parallel dasatinib + quercetin (D+Q) work in idiopathic pulmonary fibrosis and diabetic kidney disease provides a reference point for what Phase 2 senolytic data looks like when it is published: meaningful intermediate endpoint signals, limited sample sizes, and further trials needed for clinical outcome conclusions.

Fisetin’s position relative to the D+Q combination is worth spelling out. D+Q has more published Phase 2 human data to date; fisetin has stronger comparative preclinical senolytic data from the 2017 Mayo screening. D+Q pairs a prescription oncology drug (dasatinib) that requires clinical supervision with a dietary flavonoid. Fisetin is a single compound available as a dietary supplement without prescription requirements. The practical tradeoff is that D+Q’s human evidence base is somewhat deeper, while fisetin’s supplement accessibility is considerably higher for those independently following this research.

The comparison with ergothioneine is relevant for readers tracking the broader Japanese longevity supplement space: EGT and fisetin operate on entirely different mechanisms. EGT acts primarily as a mitochondrial antioxidant accumulated via the dedicated OCTN1 cellular transporter — covered in the ergothioneine and Japanese mushrooms article. Fisetin’s primary research track is senolytic activity and SASP suppression. The two mechanisms are non-overlapping rather than redundant, which means readers interested in both are not chasing the same target through two supplements. Similarly, the FOXO3 longevity genetics research — summarized in the FOXO3 and Okinawan ancestry article — describes a genetic pathway for cellular stress resistance and autophagy that intersects with, but is upstream of, the senescent cell accumulation picture fisetin addresses.

Fisetin supplements: what to look for when buying

The commercial fisetin supplement market expanded substantially after the 2018 Yousefzadeh paper received mainstream science coverage. Product quality varies in ways that matter before committing to a purchase.

Dose specification: the most commonly referenced commercial dose range is 100–500 mg per serving. No published human dose-ranging trial has established what dose is required to produce meaningful senescent cell biomarker changes in humans, so commercial dose ranges are extrapolated from preclinical work rather than derived from established human protocols. Buyer expectations about dose should account for that uncertainty explicitly.

Purity and third-party testing: fisetin is not a standardized regulated ingredient under FDA dietary supplement rules. Independent laboratory certificates of analysis covering purity and the absence of heavy metal contamination are more informative than manufacturer label claims. Look for a COA link in the product listing or on the brand’s website before purchasing.

Formulation considerations: fisetin as an isolated polyphenol has limited water solubility, which affects oral bioavailability. Some formulations use phospholipid complexing or related absorption-enhancement approaches. Whether these approaches meaningfully improve plasma fisetin concentrations in humans compared to unformulated fisetin has limited pharmacokinetic support; the preclinical studies used unformulated fisetin in rodent models.

Life Extension Fisetin at 125 mg per capsule is among the most frequently referenced products in practitioner discussions about fisetin supplementation: search Life Extension Fisetin 125mg on Amazon.

NOW Foods Fisetin at 100 mg per capsule is a lower-priced option in the same dose range: search NOW Foods Fisetin 100mg on Amazon.

Double Wood Supplements also produces a fisetin product that appears consistently across independent supplement review comparisons: search Double Wood Fisetin supplement on Amazon.

For readers who want to compare brands before committing: search fisetin senolytic supplement capsules on Amazon.

Side effects, interactions, and who should discuss this with a clinician first

Fisetin has a long history as a dietary component through strawberry and apple consumption, which provides indirect context for dietary-level safety. The supplement safety profile at the doses being discussed for senolytic protocols — typically 100–500 mg/day — is less well characterized from controlled human studies.

CYP enzyme interactions: fisetin inhibits cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9, in cell culture at higher concentrations. CYP3A4 processes a broad range of medications including statins, calcium channel blockers, anticoagulants, and immunosuppressants. Whether fisetin at commercially available supplement doses produces clinically relevant CYP inhibition in humans has not been established in human pharmacokinetic interaction studies. Anyone taking medications metabolized by these enzymes — a large proportion of commonly prescribed drugs — should discuss fisetin supplementation with their prescribing physician before starting.

Anticoagulant and antiplatelet medications: fisetin has shown anti-platelet aggregation activity in cell culture and animal models. The clinical significance for individuals taking warfarin, aspirin, or clopidogrel has not been established in human studies, but the mechanistic overlap warrants a conversation with a prescribing clinician before adding fisetin.

Hormonal activity: fisetin has mild estrogenic activity in cell culture systems. The relevance at supplement doses in humans is not established. Individuals with hormone-sensitive conditions should discuss with a clinician.

Pregnancy and lactation: no controlled human safety data exists for supplement-level fisetin intake. Standard precautionary avoidance applies.

Active cancer treatment: the interaction between flavonoid supplementation and chemotherapy or radiation has a complex research history. Fisetin-specific data in oncological treatment contexts does not exist. The general precautionary position for any compound with antioxidant and CYP-inhibitory activity during active treatment is to discuss with the treating oncologist first.

Who should ask a clinician before starting: anyone taking multiple medications — particularly those metabolized by CYP3A4 or CYP2C9; anyone on anticoagulant or antiplatelet therapy; anyone with hormone-sensitive conditions; anyone currently in active cancer treatment; anyone pregnant or nursing. The research case for fisetin among natural senolytic candidates is the most evidence-grounded of the polyphenols studied so far, but that case exists at the preclinical stage. The appropriate response to that evidence, particularly while Phase 2 human trial results are pending, is attentive interest rather than confident independent dosing.

If you are following the aging biology science that surrounds this research, the cellular senescence mechanisms article and the FOXO3 longevity gene research provide the framework that makes the fisetin findings legible — both what they mean and what evidence would be needed to move them from promising preclinical data to something a clinician could act on with confidence.

---

Sources: Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18–28. | Kirkland JL, Tchkonia T. Cellular Senescence: A Translational Perspective. EBioMedicine. 2017;21:21–28. | Clinical trial registrations NCT02848131 and NCT02652052 (ClinicalTrials.gov). | Arai Y et al. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr. 2000 (strawberry fisetin concentration reference).